Medis International A.S Pharmaceutical Import Profile — Czech Republic (DGFT 2022–2026)

Name: Medis International A.S Pharmaceutical Import Records from India — 2 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medis International A.S — Pharmaceutical Importer Profile (2026) | 2 Products, $1.3M Trade | TransData Nexus

Medis International A.S

Pharmaceutical Importer · Czech Republic · Advanced Antifungals Focus · $1.3M Total Trade · DGFT Verified

Medis International A.S is a pharmaceutical importer based in Czech Republic with a total trade value of $1.3M across 2 products in 2 therapeutic categories. Based on 28 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Medis International A.S sources from 13 verified Indian suppliers, with Mylan Laboratories Limited accounting for 37.1% of imports.

Medis International A.S — Import Portfolio & Supplier Network

Medis International A.S import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medis International A.S?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$4.8M	204	37.1%
Torrent Pharmaceuticals Limited	$2.1M	71	16.2%
Msn Laboratories Private Limited

What Formulations Does Medis International A.S Import?

Formulation	Value	Ships
Atorvastatin medreg 20 MG flm tbl	$539.5K	46
Ibuprofen dr. max 400MG. capsule moi mfgdate: 01/2024 exp date	$296.6K	6
Tramadol paracetamol 37.5MG/325MG film	$262.5K	6
Atorvastatin medreg 80 MG flm tbl	$255.6K	14
Solifenacin succinate tablets 5 MG	$250.0K	5
Olanzapine tablets 10 MG packs 9000s	$200.0K	4
Other-lercanidipine medreg 20MG	$194.9K	4
Ibuprofen tablets [400MG][bulk	$181.5K	4
Solifenacin TAB 10MG eu (packs : 30000's bsp)	$157.0K	4
Ibuprofen dr.max 400 MG.CAPS makke	$150.0K	3
Posaconazole 100 MG gr tablets (561.720x 1000 nos tablets)(batch no.ck300,ck301,ck302 & ck342	$150.0K	3
Ibuprofen dr. max 400MG. CAPS makke kapsuly mfg date: 12/2023 exp date	$148.6K	3
Ibuprofen dr. max 400MG. capsule moi mfgdate: 04/2024 exp date	$143.4K	3
Atorvastatin medreg 10 MG flm tbl	$135.3K	16
Olanzapine tablets 5 MG	$132.1K	4

Medis International A.S imports 266 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Posaconazole	Advanced Antifungals	$1.3M	25	0.8%	2
2	Bisacodyl	Gastrointestinal	$70.7K	3	0.8%	16

Medis International A.S imports 2 pharmaceutical products across 2 categories into Czech Republic totaling $1.3M.

Medis International A.S — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Medis International a.s. is a Czech pharmaceutical company specializing in contract packaging and quality control services for medicinal products. Established in 2007, the company is headquartered in Prague, with a production facility located in Bolatice, near Opava. The Bolatice plant, operational since December 2009, is equipped with automated packaging lines capable of handling up to 220 million tablets or capsules annually. Medis International a.s. serves pharmaceutical companies both domestically and internationally, offering services that comply with Good Manufacturing Practice (GMP) standards. (medisinternational.cz)

2Distribution Network

Medis International a.s. operates a centralized distribution network from its Bolatice production facility. The plant's strategic location in the Opava region, approximately 45 km from Ostrava Mošnov International Airport, facilitates efficient logistics and distribution within the Czech Republic and to neighboring countries. (medisinternational.cz) The facility's design, adhering to the latest GMP requirements, ensures the safe and compliant distribution of pharmaceutical products.

3Industry Role

Medis International a.s. functions primarily as a contract packaging and quality control service provider within the Czech pharmaceutical supply chain. While the company does not engage directly in the importation or wholesale distribution of pharmaceutical products, it plays a crucial role in ensuring that imported medicines meet the stringent quality standards required for the European market. By offering comprehensive packaging and quality control services, Medis International a.s. supports pharmaceutical companies in bringing their products to market efficiently and compliantly. (medisinternational.cz)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medis International A.S

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Medis International a.s. does not import pharmaceutical products directly; instead, it provides contract packaging and quality control services to pharmaceutical companies. Therefore, the company does not exhibit supplier concentration in the traditional sense. Its business model focuses on offering services to a diverse clientele, mitigating risks associated with dependency on a single supplier. The company's ability to serve multiple pharmaceutical companies indicates a stable and flexible relationship with its clients, allowing for adaptability in meeting various packaging and quality control requirements.

2Supply Chain Resilience

As a contract packaging and quality control service provider, Medis International a.s. does not manage its own supply chain for pharmaceutical products. Instead, it relies on the supply chains of its pharmaceutical clients, ensuring that all imported medicines comply with Good Manufacturing Practice (GMP) standards. The company's facility in Bolatice is designed to meet the latest GMP requirements, providing a resilient environment for packaging and quality control operations.

3Strategic Implications

Importing Pharmaceuticals into Czech Republic — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Czech Republic

1Regulatory Authority & Framework

In the Czech Republic, the State Institute for Drug Control (SÚKL) is the primary regulatory authority overseeing the authorization and regulation of medicinal products. The legal framework governing pharmaceutical imports includes Act No. 378/2007 Coll., on Pharmaceuticals, as amended, and its implementing regulations, which set forth the requirements for the manufacture, distribution, and marketing authorization of medicinal products. (sukl.gov.cz) These regulations ensure that all pharmaceutical products, including those imported from countries like India, meet the necessary standards for safety, efficacy, and quality before entering the Czech market.

2Import Licensing & GMP

The importation of pharmaceutical products into the Czech Republic is subject to specific licensing requirements. Certain products, including those from the chemical and pharmaceutical industries, require import licenses as outlined in Act No. 62/2000 Coll. and Government Regulation No. 185/2000 Coll. Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards, which are enforced by SÚKL. This ensures that all medicinal products, regardless of their country of origin, meet the quality standards necessary for distribution within the Czech Republic.

Quality & Labeling

Medis International A.S — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Medis International a.s. specializes in contract packaging and quality control services for pharmaceutical products, focusing on ensuring that imported medicines meet the stringent standards required for the European market. The company's services are driven by the demand for high-quality packaging and compliance with regulatory requirements, which are essential for the successful market entry and distribution of pharmaceutical products in Europe. By offering comprehensive solutions, Medis International a.s. supports pharmaceutical companies in navigating the complexities of the European market, ensuring that their products are both compliant and market-ready.

2Sourcing Profile

Medis International a.s. does not engage in the direct sourcing of pharmaceutical products; instead, it provides contract packaging and quality control services to pharmaceutical companies. The company's role is to ensure that imported products, including those from India, meet the necessary quality standards and regulatory requirements for the European market. By offering these services, Medis International a.s. supports pharmaceutical companies in bringing their products to market efficiently and compliantly.

3Market Positioning

Seller's Guide — How to Become a Supplier to Medis International A.S

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For Indian pharmaceutical exporters, partnering with Medis International a.s. presents an opportunity to access the European market through a service provider that ensures compliance with European standards. By leveraging Medis International a.s.'s expertise in packaging and quality control, Indian exporters can enhance the marketability and acceptance of their products in Europe. This partnership can facilitate smoother market entry and distribution, addressing potential challenges related to regulatory compliance and quality assurance.

2Requirements & Qualifications

Indian pharmaceutical exporters seeking to supply products to the Czech Republic must ensure that their products comply with the European Union's Good Manufacturing Practice (GMP) standards. Additionally, products must meet the labeling requirements, including providing information in the Czech language. Serialization mandates must also be adhered to, ensuring traceability and preventing counterfeit products. By meeting these requirements, Indian exporters can facilitate the acceptance and distribution of their products within the Czech market.

3How to Approach

Frequently Asked Questions — Medis International A.S

What products does Medis International A.S import from India?

Medis International A.S imports 2 pharmaceutical products across 2 categories. Top imports: Posaconazole ($1.3M), Bisacodyl ($70.7K).

Who supplies pharmaceuticals to Medis International A.S from India?

Medis International A.S sources from 13 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (37.1% of imports, $4.8M).

What is Medis International A.S's total pharmaceutical import value?

Medis International A.S's total pharmaceutical import value from India is $1.3M, based on 28 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medis International A.S focus on?

Medis International A.S imports across 2 categories. The largest: Advanced Antifungals (94.6%), Gastrointestinal (5.4%).

Get Full Medis International A.S Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.